Pharmacokinetics of Gepotidacin in Renal Impairment

Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. In this phase 1, nonrandomized, open‐label, parallel‐group, multicenter, multipart study, the pharmacokinetics, safety, and tolerability of a single intravenous (IV) dose of gepotidacin 750 mg over 2 hours were evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Mohammad, Tiffany, Courtney, Raychaudhuri, Aparna, Nguyen, Dung, Tai, Guoying, Alcorn, Harry, Preston, Richard A., Marbury, Thomas, Dumont, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384084/
https://www.ncbi.nlm.nih.gov/pubmed/32429000
http://dx.doi.org/10.1002/cpdd.807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384084/
https://www.ncbi.nlm.nih.gov/pubmed/32429000
http://dx.doi.org/10.1002/cpdd.807

Ejemplares similares